Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 15/20 | 0.49 |
| ▸ | JAK3 | P52333 | 15/20 | 0.49 |
| ▸ | JAK2 | O60674 | 13/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524081 | 0.90 | PTK2 (0.43) | PTK2JAK3JAK2ALKBTK | |
| SCHEMBL14576576 | 0.90 | PTK2 (0.51) | PTK2JAK3JAK2 | |
| SCHEMBL14576814 | 0.86 | PTK2 (0.48) | PTK2JAK3JAK2LCKBTK | |
| SCHEMBL15524489 | 0.85 | PTK2 (0.57) | PTK2JAK3JAK2 | |
| SCHEMBL14648859 | 0.84 | ALK (0.55) | PTK2ALK | |
| SCHEMBL15524542 | 0.84 | FLT4 (0.45) | PTK2JAK3JAK2NAMPTALK | |
| SCHEMBL15524518 | 0.83 | PTK2 (0.45) | PTK2JAK3 | |
| SCHEMBL14643595 | 0.83 | PTK2 (0.50) | PTK2JAK3JAK2LCKBTK | |
| SCHEMBL15524240 | 0.82 | PTK2 (0.50) | PTK2JAK3JAK2ALKIGF1R | |
| SCHEMBL14577195 | 0.82 | PTK2 (0.53) | PTK2JAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | PTK2 240/4885JAK3 26/4885JAK2 143/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | PTK2 260/4885JAK3 26/4885JAK2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.